Health Dictionary
Reliable, easy-to-read patient information on common medical conditions — written in plain language, free of jargon, and grounded in current evidence. Browse the most frequent diagnoses, understand what they mean for everyday life, and learn which steps and questions help you have a focused conversation with your doctor.
DAB2
Introduction
Disabled homolog 2 is a protein that in humans is encoded by the DAB2 gene.[1][2]
Function
Function
DAB2 mRNA is expressed in normal ovarian epithelial cells but is down-regulated or absent from ovarian carcinoma cell lines. The 770-amino acid predicted protein has an overall 83% identity with the mouse p96 protein, a putative mitogen-responsive phosphoprotein; homology is strongest in the amino-terminal end of the protein in a region corresponding to the phosphotyrosine interaction domain. The down-regulation of DAB2 may play an important role in ovarian carcinogenesis. This gene was initially named DOC2 (for Differentially expressed in Ovarian Cancer) and is distinct from the DOC2A and DOC2B genes (for double C2-like domains, alpha and beta).[3]
References
References
- ↑ Albertsen HM, Smith SA, Melis R, Williams B, Holik P, Stevens J, White R (January 1997). “Sequence, genomic structure, and chromosomal assignment of human DOC-2”. Genomics. 33 (2): 207–13. doi:10.1006/geno.1996.0185. PMID 8660969.
- ↑ Mok SC, Chan WY, Wong KK, Cheung KK, Lau CC, Ng SW, Baldini A, Colitti CV, Rock CO, Berkowitz RS (June 1998). “DOC-2, a candidate tumor suppressor gene in human epithelial ovarian cancer”. Oncogene. 16 (18): 2381–7. doi:10.1038/sj.onc.1201769. PMID 9620555.
- ↑ “Entrez Gene: DAB2 disabled homolog 2, mitogen-responsive phosphoprotein (Drosophila)”.
- ↑ 4.0 4.1 Zhou J, Scholes J, Hsieh JT (February 2003). “Characterization of a novel negative regulator (DOC-2/DAB2) of c-Src in normal prostatic epithelium and cancer”. J. Biol. Chem. 278 (9): 6936–41. doi:10.1074/jbc.M210628200. PMID 12473651.
- ↑ 5.0 5.1 He J, Xu J, Xu XX, Hall RA (July 2003). “Cell cycle-dependent phosphorylation of Disabled-2 by cdc2”. Oncogene. 22 (29): 4524–30. doi:10.1038/sj.onc.1206767. PMID 12881709.
- ↑ Wang Z, Tseng CP, Pong RC, Chen H, McConnell JD, Navone N, Hsieh JT (April 2002). “The mechanism of growth-inhibitory effect of DOC-2/DAB2 in prostate cancer. Characterization of a novel GTPase-activating protein associated with N-terminal domain of DOC-2/DAB2”. J. Biol. Chem. 277 (15): 12622–31. doi:10.1074/jbc.M110568200. PMID 11812785.
- ↑ 7.0 7.1 Hocevar BA, Mou F, Rennolds JL, Morris SM, Cooper JA, Howe PH (June 2003). “Regulation of the Wnt signaling pathway by disabled-2 (Dab2)”. EMBO J. 22 (12): 3084–94. doi:10.1093/emboj/cdg286. PMC 162138. PMID 12805222.
- ↑ Oleinikov AV, Zhao J, Makker SP (May 2000). “Cytosolic adaptor protein Dab2 is an intracellular ligand of endocytic receptor gp600/megalin”. Biochem. J. 347 Pt 3: 613–21. doi:10.1042/0264-6021:3470613. PMC 1220996. PMID 10769163.
- ↑ Morris SM, Arden SD, Roberts RC, Kendrick-Jones J, Cooper JA, Luzio JP, Buss F (May 2002). “Myosin VI binds to and localises with Dab2, potentially linking receptor-mediated endocytosis and the actin cytoskeleton”. Traffic. 3 (5): 331–41. doi:10.1034/j.1600-0854.2002.30503.x. PMID 11967127.
- ↑ Inoue A, Sato O, Homma K, Ikebe M (March 2002). “DOC-2/DAB2 is the binding partner of myosin VI”. Biochem. Biophys. Res. Commun. 292 (2): 300–7. doi:10.1006/bbrc.2002.6636. PMID 11906161.
- ↑ 11.0 11.1 Hocevar BA, Smine A, Xu XX, Howe PH (June 2001). “The adaptor molecule Disabled-2 links the transforming growth factor beta receptors to the Smad pathway”. EMBO J. 20 (11): 2789–801. doi:10.1093/emboj/20.11.2789. PMC 125498. PMID 11387212.
Further reading
Further reading
- Mok SC, Wong KK, Chan RK, Lau CC, Tsao SW, Knapp RC, Berkowitz RS (1994). “Molecular cloning of differentially expressed genes in human epithelial ovarian cancer”. Gynecol. Oncol. 52 (2): 247–52. doi:10.1006/gyno.1994.1040. PMID 8314147.
- Bonaldo MF, Lennon G, Soares MB (1996). “Normalization and subtraction: two approaches to facilitate gene discovery”. Genome Res. 6 (9): 791–806. doi:10.1101/gr.6.9.791. PMID 8889548.
- Xu XX, Yi T, Tang B, Lambeth JD (1998). “Disabled-2 (Dab2) is an SH3 domain-binding partner of Grb2”. Oncogene. 16 (12): 1561–9. doi:10.1038/sj.onc.1201678. PMID 9569023.
- Fazili Z, Sun W, Mittelstaedt S, Cohen C, Xu XX (1999). “Disabled-2 inactivation is an early step in ovarian tumorigenicity”. Oncogene. 18 (20): 3104–13. doi:10.1038/sj.onc.1202649. PMID 10340382.
- Tseng CP, Ely BD, Pong RC, Wang Z, Zhou J, Hsieh JT (1999). “The role of DOC-2/DAB2 protein phosphorylation in the inhibition of AP-1 activity. An underlying mechanism of its tumor-suppressive function in prostate cancer”. J. Biol. Chem. 274 (45): 31981–6. doi:10.1074/jbc.274.45.31981. PMID 10542228.
- Oleinikov AV, Zhao J, Makker SP (2000). “Cytosolic adaptor protein Dab2 is an intracellular ligand of endocytic receptor gp600/megalin”. Biochem. J. 347 Pt 3 (3): 613–21. doi:10.1042/0264-6021:3470613. PMC 1220996. PMID 10769163.
- Sheng Z, Sun W, Smith E, Cohen C, Sheng Z, Xu XX (2000). “Restoration of positioning control following Disabled-2 expression in ovarian and breast tumor cells”. Oncogene. 19 (42): 4847–54. doi:10.1038/sj.onc.1203853. PMID 11039902.
- Sheng Z, He J, Tuppen JA, Sun W, Fazili Z, Smith ER, Dong FB, Xu XX (2000). “Structure, sequence, and promoter analysis of human disabled-2 gene (DAB2)”. Genomics. 70 (3): 381–6. doi:10.1006/geno.2000.6383. PMID 11161789.
- Morris SM, Cooper JA (2001). “Disabled-2 colocalizes with the LDLR in clathrin-coated pits and interacts with AP-2”. Traffic. 2 (2): 111–23. doi:10.1034/j.1600-0854.2001.020206.x. PMID 11247302.
- Zhou J, Hsieh JT (2001). “The inhibitory role of DOC-2/DAB2 in growth factor receptor-mediated signal cascade. DOC-2/DAB2-mediated inhibition of ERK phosphorylation via binding to Grb2”. J. Biol. Chem. 276 (30): 27793–8. doi:10.1074/jbc.M102803200. PMID 11371563.
- Hocevar BA, Smine A, Xu XX, Howe PH (2001). “The adaptor molecule Disabled-2 links the transforming growth factor beta receptors to the Smad pathway”. EMBO J. 20 (11): 2789–801. doi:10.1093/emboj/20.11.2789. PMC 125498. PMID 11387212.
- Wang Z, Tseng CP, Pong RC, Chen H, McConnell JD, Navone N, Hsieh JT (2002). “The mechanism of growth-inhibitory effect of DOC-2/DAB2 in prostate cancer. Characterization of a novel GTPase-activating protein associated with N-terminal domain of DOC-2/DAB2”. J. Biol. Chem. 277 (15): 12622–31. doi:10.1074/jbc.M110568200. PMID 11812785.
- Inoue A, Sato O, Homma K, Ikebe M (2002). “DOC-2/DAB2 is the binding partner of myosin VI”. Biochem. Biophys. Res. Commun. 292 (2): 300–7. doi:10.1006/bbrc.2002.6636. PMID 11906161.
- Mishra SK, Keyel PA, Hawryluk MJ, Agostinelli NR, Watkins SC, Traub LM (2002). “Disabled-2 exhibits the properties of a cargo-selective endocytic clathrin adaptor”. EMBO J. 21 (18): 4915–26. doi:10.1093/emboj/cdf487. PMC 126284. PMID 12234931.
- Morris SM, Tallquist MD, Rock CO, Cooper JA (2002). “Dual roles for the Dab2 adaptor protein in embryonic development and kidney transport”. EMBO J. 21 (7): 1555–64. doi:10.1093/emboj/21.7.1555. PMC 125955. PMID 11927540.
- Morris SM, Arden SD, Roberts RC, Kendrick-Jones J, Cooper JA, Luzio JP, Buss F (2002). “Myosin VI binds to and localises with Dab2, potentially linking receptor-mediated endocytosis and the actin cytoskeleton”. Traffic. 3 (5): 331–41. doi:10.1034/j.1600-0854.2002.30503.x. PMID 11967127.
- Zhou J, Scholes J, Hsieh JT (2003). “Characterization of a novel negative regulator (DOC-2/DAB2) of c-Src in normal prostatic epithelium and cancer”. J. Biol. Chem. 278 (9): 6936–41. doi:10.1074/jbc.M210628200. PMID 12473651.
- Calderwood DA, Fujioka Y, de Pereda JM, García-Alvarez B, Nakamoto T, Margolis B, McGlade CJ, Liddington RC, Ginsberg MH (2003). “Integrin beta cytoplasmic domain interactions with phosphotyrosine-binding domains: a structural prototype for diversity in integrin signaling”. Proc. Natl. Acad. Sci. U.S.A. 100 (5): 2272–7. doi:10.1073/pnas.262791999. PMC 151330. PMID 12606711.